Roe Catherine M, Anderson Michael J, Spivack Barney
Outcomes Research, Express Scripts, Inc., Maryland Heights, Missouri, USA.
J Am Geriatr Soc. 2002 May;50(5):836-42. doi: 10.1046/j.1532-5415.2002.50208.x.
To compare the prevalence of anticholinergic use in older adults with probable dementia with that of a matched comparison group of older adults who were unlikely to have dementia and to examine the extent to which patients taking donepezil concomitantly use anticholinergic medications.
Retrospective study.
Community-based older adults receiving medications through a pharmacy benefit management company.
Eight hundred thirty-six patients aged 65 and older. Patients taking donepezil (n = 418) constituted the treatment group. Patients not taking donepezil (n = 418) constituted the comparison group. Each treatment group member was matched with a comparison group member on the basis of age, sex, and number of drugs taken for chronic conditions.
The prevalence of anticholinergic use was compared in the treatment and comparison groups over a 3- to 12-month follow-up period using pharmacy claims data. The proportion of follow-up period days that treatment group members concomitantly used donepezil and anticholinergics was also examined.
Older adults with probable dementia were more likely to use anticholinergics than matched comparison group patients (33.0% vs 23.4%; P =.001). Of treatment group members receiving anticholinergics, 26.1% used multiple anticholinergic medications. Treatment group members who received anticholinergics used those drugs concomitantly with donepezil on a mean of 28.4% of follow-up period days.
Community-based, commercially insured, older adults with probable dementia are more likely to take anticholinergics than matched controls. Patients taking donepezil frequently use an anticholinergic medication concomitantly. This study suggests that prescribing for older adults with dementia could be improved, especially if cognitive enhancing agents are being considered.
比较可能患有痴呆症的老年人与不太可能患有痴呆症的匹配老年对照组中抗胆碱能药物的使用情况,并研究同时服用多奈哌齐的患者使用抗胆碱能药物的程度。
回顾性研究。
通过药房福利管理公司接受药物治疗的社区老年人。
836名65岁及以上的患者。服用多奈哌齐的患者(n = 418)构成治疗组。未服用多奈哌齐的患者(n = 418)构成对照组。每个治疗组成员在年龄、性别和用于慢性病的药物数量方面与一个对照组成员相匹配。
使用药房报销数据,在3至12个月的随访期内比较治疗组和对照组中抗胆碱能药物的使用情况。还检查了治疗组成员在随访期内同时使用多奈哌齐和抗胆碱能药物的天数比例。
可能患有痴呆症的老年人比匹配的对照组患者更有可能使用抗胆碱能药物(33.0%对23.4%;P = 0.001)。在接受抗胆碱能药物治疗的治疗组成员中,26.1%使用了多种抗胆碱能药物。接受抗胆碱能药物治疗的治疗组成员在随访期内平均有28.4%的天数同时使用这些药物和多奈哌齐。
基于社区、有商业保险、可能患有痴呆症的老年人比匹配的对照组更有可能服用抗胆碱能药物。服用多奈哌齐的患者经常同时使用抗胆碱能药物。这项研究表明,对患有痴呆症的老年人的处方可以改进,特别是在考虑使用认知增强剂时。